assess
qualiti
molecular
detect
respiratori
virus
clinic
diagnost
laboratori
studi
design
respiratori
viru
profici
panel
produc
dilut
stock
respiratori
virus
provid
test
four
refer
laboratori
panel
consist
strong
posit
posit
low
posit
neg
sampl
influenza
virus
b
respiratori
syncyti
viru
parainfluenza
virus
adenoviru
serotyp
human
rhinoviru
serotyp
human
coronavirus
panel
sent
particip
result
inform
methodolog
collect
result
laboratori
return
result
five
submit
complet
data
set
analysi
result
combin
sampl
correctli
identifi
particip
high
posit
posit
low
posit
sampl
respect
one
fals
posit
report
data
set
overal
score
assay
use
differ
methodolog
laboratori
perform
depend
methodolog
inhous
methodolog
could
achiev
optim
result
depend
care
optimis
procedur
specif
laboratori
conclus
first
profici
panel
show
gener
particip
perform
well
although
also
highlight
area
improv
particip
order
gener
robust
result
use
clinic
diagnost
detect
respiratori
virus
clinic
sampl
import
effect
patient
manag
infect
control
mani
virus
involv
respiratori
infect
includ
influenza
virus
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
adenovirus
adv
human
rhinovirus
hrv
human
coronavirus
hcov
nlhong
kong
sever
acut
respiratori
syndrom
coronaviru
sarscov
human
metapneumovirus
hmpv
mani
infect
indistinguish
clinic
featur
alon
requir
rapid
laboratori
investig
optim
patient
manag
infect
control
detect
respiratori
virus
becom
clinic
import
possibl
antivir
treatment
increas
virus
hrv
hcov
initi
consid
caus
mild
infect
frequent
found
associ
sever
infect
ison
et
al
van
elden
et
al
viral
cultur
gold
standard
laboratori
diagnosi
respiratori
virus
howev
virus
grow
poorli
cell
cultur
therefor
routin
diagnosi
suboptim
exampl
hmpv
van
den
hoogen
et
al
furthermor
cultur
rel
slow
affect
clinic
valu
therefor
altern
employ
rapid
antigen
detect
test
avail
influenza
virus
b
piv
rsv
adenovirus
wide
use
routin
laboratori
shown
less
sensit
less
specif
cultur
particularli
adult
elderli
popul
casianocolon
et
al
effler
et
al
storch
amplif
assay
increasingli
use
clinic
laboratori
proven
sensit
specif
cultur
syrmi
et
al
van
elden
et
al
weinberg
et
al
weinberg
et
al
newer
realtim
pcr
format
also
enabl
rapid
test
result
templeton
et
al
convent
format
detect
larg
number
respiratori
virus
singl
test
pupp
et
al
coira
et
al
grutek
et
al
pcr
often
appropri
mean
diagnos
slow
grow
virus
van
elden
et
al
van
den
hoogen
et
al
due
difficulti
sometim
observ
cultur
current
commerci
assay
avail
respiratori
viru
test
henrickson
major
assay
appli
clinic
diagnost
laboratori
develop
inhous
standardis
problemat
format
laboratori
perform
respiratori
molecular
test
want
report
accur
reliabl
result
regardless
type
assay
use
one
best
way
assess
perform
particip
profici
programm
enabl
laboratori
evalu
perform
schirm
et
al
schloss
et
al
noordhoek
et
al
verkooyen
et
al
pilot
studi
evalu
nucleic
acid
amplif
technolog
nat
detect
respiratori
viral
pathogen
organis
qualiti
control
molecular
diagnost
qcmd
wwwqcmdorg
aim
pilot
programm
perform
compar
studi
current
nat
protocol
use
molecular
detect
varieti
respiratori
virus
aim
studi
focu
sensit
specif
nat
protocol
use
well
methodolog
employ
molecular
test
project
group
compris
qcmd
four
european
laboratori
establish
coordin
produc
materi
profici
programm
panel
laboratori
respons
product
bulk
stock
number
defin
virus
specialist
centr
virolog
svc
gartnavel
gener
hospit
glasgow
uk
influenza
virus
b
rsv
univers
medic
centr
utrecht
umcu
netherland
hrv
erasmu
medic
center
emc
rotterdam
netherland
hmpv
leiden
univers
medic
center
lumc
leiden
netherland
piv
adv
svc
stock
influenza
viru
anew
influenza
b
viru
prepar
mdck
cell
medium
rsv
clinic
isol
cultur
cell
mem
vv
fc
viral
nucleic
acid
extract
carri
use
biorobot
blood
dna
kit
qiagen
crawley
uk
realtim
pcr
taqman
probe
use
amplifi
influenza
viru
ns
gene
influenza
viru
b
matrix
gene
rsv
nucleocapsid
gene
icycl
iq
realtim
detect
system
biorad
hemel
hempstead
uk
clinic
isol
adv
cultur
cell
mem
vv
fc
subtyp
confirm
serotyp
sequenc
analysi
clinic
isol
piv
cultur
cell
subtyp
confirm
monoclon
antibodi
stain
sequenc
analysi
viru
nucleic
acid
extract
carri
qiaamp
blood
dna
mini
spin
protocol
adv
qiaamp
viral
rna
mini
spin
protocol
piv
qiagen
hilden
germani
realtim
pcr
molecular
beacon
use
amplifi
adv
hexon
gene
piv
haemagluttininneuramididas
gene
icycl
iq
realtim
detect
system
biorad
veenenda
netherland
atcc
strain
hmpv
isol
van
den
hoogen
et
al
cultur
vero
cell
mem
vv
fc
viru
nucleic
acid
extract
carri
use
magnapur
lc
total
nucleic
acid
kit
roch
appli
scienc
almer
netherland
realtim
pcr
perform
taqman
probe
amplifi
detect
nucleocapsid
gene
nucleoprotein
hmpv
abi
prism
sequenc
detect
system
appli
biosystem
nieuwerkerk
aan
de
ijssel
netherland
human
rhinovirus
hrv
donat
dr
tapani
hovi
ktl
helsinki
finland
origin
obtain
atcc
hrv
type
rivm
bilthoven
netherland
hrv
type
janssen
pharmaceutica
beers
belgium
hrv
type
grown
hela
ohio
cell
roller
tube
cultur
c
characteris
acidl
test
serotyp
sequenc
analysi
product
stock
pilot
profici
panel
virus
grown
human
diploid
fibroblast
cell
viru
nucleic
acid
extract
carri
use
magnapur
lc
total
nucleic
acid
kit
realtim
pcr
perform
abi
prism
sequenc
detect
system
taqman
probe
amplifi
noncod
region
ncr
rhinovirus
laboratori
prepar
smallscal
dilut
seri
bulk
stock
determin
lower
limit
detect
lld
viru
stock
base
realtim
cycl
threshold
c
valu
tabl
process
repeat
second
laboratori
thereaft
project
group
select
three
dilut
viru
inclus
profici
panel
bulk
dilut
stock
prepar
viru
transport
medium
vtm
except
influenza
viru
b
prepar
medium
vv
fc
bulk
dilut
stock
repeat
test
use
methodolog
data
shown
dispens
ml
aliquot
ship
dri
ice
qcmd
code
packag
distribut
particip
panel
sampl
randomis
qcmd
label
pack
distribut
particip
dri
ice
along
panel
receipt
form
instruct
leaflet
report
form
questionnair
technic
detail
panel
distribut
form
six
subpanel
panel
contain
influenza
virus
b
panel
b
piv
panel
c
rsv
hmpv
panel
hrv
panel
e
adv
panel
f
hcov
subpanel
contain
threememb
dilut
seri
viru
mix
sampl
except
panel
c
neg
sampl
laboratori
express
interest
qcmd
particip
profici
programm
molecular
detect
respiratori
virus
ask
complet
questionnair
detail
technic
aspect
assay
appli
particip
laboratori
assign
uniqu
confidenti
code
particip
request
return
result
form
technic
questionnair
either
fax
email
close
date
return
result
week
postdistribut
major
particip
submit
result
prior
close
date
number
particip
request
addit
time
complet
test
date
return
result
extend
week
result
questionnair
data
collat
valid
qcmd
particip
recontact
inform
requir
result
code
letter
sent
particip
result
receiv
result
score
point
correct
result
incorrect
equivoc
result
posit
sampl
detect
one
sampl
mix
sampl
influenza
virus
b
piv
coronaviru
panel
mix
sampl
adenoviru
rhinoviru
panel
score
requir
type
result
request
result
molecular
test
sampl
profici
panel
shown
tabl
three
dilut
differ
virus
includ
qc
panel
five
particip
provid
complet
data
set
virus
none
five
report
correct
high
posit
sampl
averag
correctli
identifi
rang
particip
mean
particip
achiev
score
hrv
panel
three
particip
detect
hrv
sampl
although
could
detect
rhinoviru
type
even
low
posit
three
particip
detect
hrv
low
posit
detect
hrv
low
posit
four
particip
score
adenoviru
panel
particip
detect
strong
posit
adenoviru
subtyp
e
sampl
particip
detect
low
posit
sampl
contrast
particip
detect
strong
posit
adenoviru
subtyp
b
sampl
particip
detect
low
posit
adenoviru
sampl
hcov
panel
particip
detect
strong
posit
sampl
none
particip
detect
low
posit
sampl
contrast
four
eight
particip
detect
low
posit
perform
laboratori
shown
tabl
mean
overal
score
rang
ninetyfour
assay
use
differ
target
realtim
pcr
nest
pcr
methodolog
respect
six
particip
use
combin
methodolog
score
obtain
individu
panel
shown
tabl
hmpv
panel
perform
best
methodolog
use
indic
integ
superscript
realtim
pcr
nest
pcr
nucleic
acid
sequenc
amplif
nasba
singl
pcr
multiplex
revers
line
blot
pcr
amplif
detect
revers
line
blot
rv
chip
assay
manufactur
bc
biotech
spa
cagliari
itali
assay
perform
nt
test
ns
score
particip
score
wherea
piv
panel
one
particip
score
score
six
particip
perform
realtim
pcr
nat
technolog
overal
rank
commerci
avail
assay
rv
chip
assay
overal
perform
assay
inhous
protocol
consist
mani
differ
paramet
technic
aspect
correl
aspect
score
given
tabl
show
maximum
score
panel
could
achiev
combin
methodolog
protocol
differ
gene
target
nat
assay
shown
tabl
four
five
nat
target
matrix
protein
influenza
viru
detect
weak
posit
sampl
wherea
two
five
nonstructur
protein
nat
detect
low
posit
sampl
nat
assay
hn
protein
piv
detect
weak
posit
sampl
wherea
nat
target
nucleoprotein
fusion
protein
detect
strong
posit
sampl
studi
describ
first
largescal
extern
qualiti
assess
scheme
molecular
detect
respiratori
virus
applic
nat
respiratori
viru
diagnosi
increas
recognis
best
method
rapid
sensit
specif
diagnost
result
van
elden
et
al
sixteen
particip
studi
develop
inhous
nat
assay
use
larg
varieti
nat
protocol
order
laboratori
assess
qualiti
inhous
assay
extern
qa
programm
develop
perform
extern
qa
panel
integr
part
accredit
qualiti
manag
clinic
diagnost
laboratori
prepar
suitabl
panel
reproduc
high
qualiti
assess
perform
nat
demand
studi
sampl
grown
cell
cultur
dilut
made
sensit
limit
specif
assay
virus
could
assess
panel
assess
smallscal
dilut
seri
prior
distribut
second
laboratori
determin
detect
limit
freezethaw
step
thereaft
stock
virus
use
prepar
final
panel
sampl
assess
one
refer
centr
prior
distribut
differ
initi
smallscal
dilut
seri
bulk
panel
sent
particip
lowest
posit
dilut
use
detect
none
particip
dilut
low
inclus
panel
howev
mani
panel
number
nat
use
detect
dilut
virus
panel
show
panel
employ
gave
good
indic
nat
perform
futur
panel
could
produc
freezedri
sampl
includ
predistribut
test
ensur
reproduc
panel
employ
qcmd
scheme
schirm
et
al
schloss
et
al
panel
employ
distribut
use
sampl
reflect
limit
detect
accord
nat
use
two
refer
laboratori
clinic
relev
detect
level
assess
known
detect
limit
requir
detect
clinic
relev
respiratori
viru
infect
limit
detect
employ
panel
probabl
reflect
good
guid
assess
sensit
nat
present
intern
refer
materi
respiratori
viru
nat
panel
provid
basi
new
intern
recognis
stock
one
fals
posit
detect
neg
sampl
hrv
panel
fals
posit
detect
panel
give
fals
posit
rate
whole
distribut
show
high
level
technic
skill
particip
laboratori
qa
programm
mani
inhous
method
use
fals
posit
rate
much
higher
schloss
et
al
reduct
fals
posit
rate
may
also
result
use
realtim
pcr
reduc
chanc
contamin
gener
correct
result
obtain
mean
strong
posit
sampl
particip
fail
detect
mean
posit
low
posit
respect
fals
neg
result
observ
either
result
sampl
detect
limit
assay
primer
probe
detect
virus
select
primer
probe
respiratori
virus
essenti
singl
nat
employ
specif
viru
need
detect
mani
variant
adenovirus
compris
six
differ
serotyp
show
larg
sequenc
variat
rna
virus
show
even
greater
sequenc
variat
lack
proof
read
capabl
viru
includ
hmpv
panel
well
characteris
van
den
hoogen
et
al
therefor
inform
would
use
gener
nat
wherea
piv
clinic
isol
publicli
avail
sequenc
inform
knowledg
sequenc
inform
would
affect
design
nat
henc
one
reason
hmpv
panel
good
perform
score
piv
poor
assay
detect
particular
viru
eg
piv
rsv
nat
laboratori
perform
well
result
poor
primer
probe
design
nonconserv
region
viru
panel
contain
one
viru
type
howev
panel
hrv
contain
three
subtyp
panel
adv
contain
two
subtyp
two
panel
show
assay
unabl
detect
certain
subtyp
even
high
posit
sampl
abl
detect
weak
posit
subtyp
result
primer
andor
probe
select
unabl
detect
virus
owe
sequenc
variat
seen
strain
therefor
particip
miss
strain
would
need
adapt
nat
order
detect
possibl
variat
result
indic
problem
use
nat
method
detect
respiratori
virus
catchal
method
care
evalu
primer
probe
need
perform
ensur
fals
neg
obtain
respiratori
virus
detect
clinic
sampl
sequenc
variat
futur
panel
virus
determin
abil
assay
detect
clinic
isol
might
includ
case
influenza
b
strain
includ
could
common
circul
strain
previou
winter
way
qualiti
nat
monitor
detect
wide
varieti
viral
strain
reason
assay
fail
detect
virus
weak
posit
lack
sensit
nat
procedur
laboratori
lot
factor
affect
nat
sensit
studi
give
indic
way
improv
sensit
pcr
format
select
gene
target
pcr
design
primer
probe
firstli
individu
compon
inhous
nat
could
achiev
maxim
sensit
one
panel
differ
sensit
probabl
due
interlaboratori
variat
anoth
factor
affect
sensit
methodolog
howev
methodolog
except
one
laboratori
use
rv
chip
assay
could
obtain
maximum
score
differ
probabl
due
interlaboratori
variat
wide
rang
perform
could
seen
methodolog
eg
realtim
pcr
select
gene
target
also
shown
affect
sensit
target
result
sensit
nat
comparison
differ
target
shown
hmpv
either
polymeras
nucleoprotein
shown
sensit
matrix
fusion
phosphoprotein
cote
et
al
maertzdorf
et
al
result
suggest
influenza
protein
good
target
hn
piv
conserv
target
also
import
primer
probe
need
detect
viru
type
case
primer
two
three
mismatch
may
work
particular
viru
although
sensit
affect
therefor
assay
detect
strong
posit
dilut
use
good
sensit
methodolog
may
need
check
mismatch
primer
probe
sequenc
potenti
includ
forward
revers
primer
achiev
good
sensit
inclus
addit
primer
probe
improv
rang
detect
shown
case
enterovirus
rhinovirus
previous
deffernez
et
al
nijhui
et
al
respiratori
viru
detect
cultur
limit
owe
sensit
cell
line
clinic
isol
particularli
appar
hrv
hcov
although
refer
strain
use
check
sensit
particular
cell
line
necessarili
mean
detect
clinic
isol
problem
equal
true
poorli
evalu
nat
nevertheless
nat
becom
valuabl
diagnost
tool
henc
need
laboratori
perform
qualiti
control
evalu
sensit
product
distribut
first
respiratori
viru
panel
show
particip
detect
strong
posit
particip
detect
low
posit
correctli
panel
also
give
good
indic
particip
improv
assay
design
well
provid
good
measur
integr
nat
employ
laboratori
